Abstract
Background
Growing evidence suggests that some coronavirus disease 2019 (COVID-19) survivors experience a wide range of long-term postacute sequelae. We examined the postacute risk and burden of new-incident cardiovascular, cerebrovascular, and other thrombotic complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a highly vaccinated multiethnic Southeast Asian population, during Delta predominance.
Methods
This cohort study used national testing and healthcare claims databases in Singapore to build a cohort of individuals who had a positive SARS-CoV-2 test between 1 September and 30 November 2021 when Delta predominated community transmission. Concurrently, we constructed a test-negative control group by enrolling individuals between 13 April 2020 and 31 December 2022 with no evidence of SARS-CoV-2 infection. Participants in both groups were followed up for a median of 300 days. We estimated risks of new-incident cardiovascular, cerebrovascular, and other thrombotic complications using doubly robust competing-risks survival analysis. Risks were reported using 2 measures: hazard ratio (HR) and excess burden (EB) with 95% confidence intervals.
Results
We included 106 012 infected cases and 1 684 085 test-negative controls. Compared with the control group, individuals with COVID-19 exhibited increased risk (HR, 1.157 [1.069–1.252]) and excess burden (EB, 0.70 [.53–.88]) of new-incident cardiovascular and cerebrovascular complications. Risks decreased in a graded fashion for fully vaccinated (HR, 1.11 [1.02–1.22]) and boosted (HR, 1.10 [.92–1.32]) individuals. Conversely, risks and burdens of subsequent cardiovascular/cerebrovascular complications increased for hospitalized and severe COVID-19 cases (compared to nonhospitalized cases).
Conclusions
Increased risks and excess burdens of new-incident cardiovascular/cerebrovascular complications were reported among infected individuals; risks can be attenuated with vaccination and boosting.
Keywords: cardiovascular, cerebrovascular, thrombotic, complications, postacute sequelae of SARS-CoV-2 infection
In the 300 days following infection, SARS-CoV-2–infected individuals exhibited increased risk of new-incident cardiovascular and cerebrovascular complications compared with test-negative controls. Risks decreased with vaccination and boosting. Conversely, risks increased for hospitalized and severe COVID-19 cases, compared to nonhospitalized cases.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with not just pulmonary but also multisystemic involvement, including cardiovascular and cerebrovascular systems [1–3]. Direct viral invasion, inflammation, and immunological responses can potentially damage the myocardium, pericardium, and conduction system [1, 2]. Similar mechanisms have been posited for neurologic manifestations in patients after coronavirus disease 2019 (COVID-19), including postinfectious autoimmune responses, hypercoagulability, endotheliopathy, and direct neuroinvasion [3]. Persistence of such damage can result in long-term sequelae [2, 3].
Multiple large retrospective cohort studies have reported increased long-term incidence of cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors up to 1 year postinfection [4–11]. The majority of these studies, however, were confined to earlier waves driven by ancestral SARS-CoV-2 strains [4–7, 9, 10]. Newer SARS-CoV-2 variants, such as Omicron, were associated with lower odds of prolonged symptoms at 3–6 months from infection compared with pre-Delta variants [12, 13]. Whether differences in symptomatology translate into reduced long-term sequelae is at present unclear. Furthermore, most studies either predated vaccination [7, 9, 10] or excluded vaccinated individuals [8]. Emerging evidence suggests that vaccination is associated with a reduced risk of major adverse cardiovascular/cerebrovascular events (MACE) after SARS-CoV-2 infection [14, 15] and reduced risk of persistent post-COVID-19 symptoms, known as long COVID [13]. A study conducted during emergence of the Delta variant, utilizing the US Veterans Affairs database, demonstrated some degree of protection with vaccination, though vaccinated individuals still had higher risk of postacute sequelae at 6 months, compared with contemporary uninfected controls [11]. Given the large and growing number of people with COVID-19, even a modestly increased risk postacute infection may translate into a substantial rise in overall disease burden, with significant consequences. An analysis early on in the pandemic estimated that long COVID might result in $2.6 trillion of cost, attributable to reductions in length as well as quality of life [16]; however, such assumptions may not hold in the current context of widely available vaccination and emergence of milder SARS-CoV-2 variants.
We retrospectively constructed a national cohort of individuals infected during a 3-month period when transmission of the Delta variant predominated in Singapore, a multiethnic Southeast Asian city-state. This cohort was compared against a test-negative control group comprising infection-naive individuals, and followed longitudinally to estimate the 300-day risk and excess burdens of new-incident prespecified cardiovascular, cerebrovascular, and other thrombotic complications.
METHODS
Study Setting and Databases
We used the national healthcare claims database to ascertain incidence of cardiovascular, cerebrovascular, and other thrombotic complications for infected cases and uninfected test-negative controls before and after SARS-CoV-2 infection, in a retrospective cohort study. Inpatient care is predominantly provided by public hospitals, which account for 77.8% of admissions; care is financed by reimbursement claims against a national medical savings scheme [17]. SARS-CoV-2 infection status (either positive polymerase chain reaction [PCR] or rapid antigen test [RAT]) was determined based on data collected from national databases maintained by the Ministry of Health (MOH), Singapore. Throughout the pandemic period, individuals with acute respiratory illness (ARI) were strongly encouraged via public health messaging to seek consultation for free SARS-CoV-2 testing, which was provided at all public primary care clinics (polyclinics) and Public Health Preparedness Clinics (PHPCs), a nationwide network of >1000 private general practitioner clinics [18]. Testing for SARS-CoV-2 (PCR/RAT) was compulsory for all individuals who presented with ARI symptoms to any healthcare provider, and positive cases were legally required to be notified to MOH [18]. Severity of initial infection was classified by care setting (mild disease: outpatient management only); hospitalized cases (intermediate severity); and severe disease, defined as hospitalized cases who additionally required oxygen supplementation or intensive care unit/high-dependency admission. All healthcare facilities notified MOH of hospitalized cases and severe infections [18].
Vaccination Program and Waves of SARS-CoV-2 Transmission in Singapore
Two mRNA vaccines were approved under Singapore’s national vaccination program: BNT162b2 (Pfizer) and mRNA-1273 (Moderna) [19]. A complete vaccine regimen involved 2 doses 3–8 weeks apart. In September 2021, persons aged ≥60 years were recommended to receive a booster 6–9 months after the second dose. By the end of November 2021, 94% had received 2 doses and 24% had received a booster [20]. The Delta variant was first detected in April 2021, predominating community transmission (≥90% of sequenced cases on national genomic surveillance) by October 2021; Delta predominated up to January 2022 when Omicron BA.1/2 replaced Delta as the dominant strain [21].
Cohort
A flowchart of cohort construction from participants enrolled between 1 September 2021 and 30 November 2022 is provided in Figure 1. We enrolled individuals who were older than 18 years and were Singapore citizens or permanent residents.
Figure 1.
Flowchart of cohort construction. Abbreviations: ARI, acute respiratory illness; COVID-19, coronavirus disease 2019; PHPCs, Public Health Preparedness Clinics; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; T0, index date of infection.
Cases were taken as those who were infected with SARS-CoV-2 for the first time during the period when transmission of the Delta variant predominated (1 September–30 November 2021), with the index date of infection (T0) taken as the date of first positive PCR/RAT. We excluded individuals who died within 30 days or had reinfections within 300 days of T0. Controls were taken as individuals who presented to primary care (polyclinics/PHPCs) from 13 April 2020 to 31 December 2022 with ARI symptoms and tested negative for SARS-CoV-2. They were randomly assigned a T0 following the distribution of infection dates among cases, and those who died within 30 days or had their first SARS-CoV-2 infection within 300 days of assigned T0 were excluded. Individuals with missing demographic data were also excluded.
Prespecified Outcomes
New-incident cardiovascular, cerebrovascular, and other thrombotic complications in the postacute phase of COVID-19 were assessed during a follow-up period beginning 31 days post-T0 and ending 300 days post-T0. Diagnoses were based on International Classification of Diseases, Tenth Revision codes recorded in the Singapore national healthcare claims database, with reference to previous work on postacute sequelae of COVID-19 [5, 11, 22–24]. Cerebrovascular complications included stroke and transient ischemic attack (TIA). Cardiovascular complications included the following: dysrhythmias, including atrial fibrillation/flutter, tachycardia, bradycardia, and other arrhythmias; ischemic heart disease (IHD), including acute coronary disease, myocardial infarction, ischemic cardiomyopathy, and angina; other cardiac disorders, including heart failure, nonischemic cardiomyopathy, cardiac arrest, and cardiogenic shock; and inflammatory heart disease, including pericarditis and myocarditis. Thrombotic complications included pulmonary embolism, deep venous thrombosis, superficial venous thrombosis, and arterial thromboses. We defined 2 additional composite outcomes: MACE, which included the first incidence of myocardial infarction, stroke, heart failure, ventricular arrhythmia, or sudden cardiac death; and the composite of any new-incident cardiovascular, cerebrovascular, or other thrombotic complication.
Statistical Analysis
We estimated the risks and excess burdens of prespecified new-incident cardiovascular, cerebrovascular, and other thrombotic complications for the SARS-CoV-2–infected group compared with uninfected test-negative controls, at 300 days from T0. For estimation of risks for each new-incident complication, a subcohort of individuals without history of the complication being reported was constructed. Individuals were excluded from each subcohort if they had reported in the past 5 years the specific complication being studied. Baseline characteristics of the SARS-CoV-2–infected and test-negative control groups, along with standardized mean difference (SMD) between groups, were computed.
We then adjusted for differences in baseline characteristics between comparison groups through inverse probability weighting, incorporating all available covariates: demographic characteristics (age, sex, ethnicity), socioeconomic status (housing type), vaccination status (not vaccinated, vaccinated, vaccinated and boosted), and comorbidity burden as indicated by constituent conditions within the Charlson comorbidity index. Although Charlson comorbidity index contained cardiovascular and cerebrovascular conditions including myocardial infarction, heart failure, stroke, and TIA, there was no overlap with subsequent outcome variables as individuals with preexisting cardiovascular/cerebrovascular conditions were already excluded at the subcohort construction stage. Housing type is a key marker of socioeconomic status in urbanized Singapore, where the majority (≥90%) stay in public housing under a tiered subsidy scheme; smaller-sized flats are more heavily subsidized and have caps on eligibility based on household income [25].
In each subcohort, a propensity score of belonging to the infected group was computed using a logistic regression that used the abovementioned covariates as explanatory terms. Inverse probability weights were computed as 1 / propensity score for cases; and 1 / (1 – propensity score) for test-negative controls. SMDs were used to assess covariate balance after inverse probability weighting.
Hazard ratios (HRs) of incident complications between the SARS-CoV-2–infected and test-negative control groups were then estimated using cause-specific hazard models with death taken as a competing risk, with inverse probability weights applied. A doubly robust approach was employed for each model, where covariates used to construct inverse probability weights were included in each model specification as explanatory variables. This approach was used to prevent model misspecification in the generation of inverse probability weights or HRs in subsequent analyses.
Burden per 1000 individuals at 300 days of follow-up and the excess burden of cardiovascular, cerebrovascular, and other thrombotic complications were estimated on the basis of the difference between the estimated incidence rates in both groups. Excess burdens here were defined as the increase/decrease in incidence rate in SARS-CoV-2–infected individuals versus test-negative individuals.
Previous studies have shown a dose-response relationship between increased severity of initial infection, older age, female sex, and full vaccination with postacute sequelae of SARS-CoV-2 infection [26]. We therefore also examined effect modification, by conducting analyses in subgroups by age (18–65 years, ≥66 years), ethnicity (Chinese, Malay, Indian, or other), sex (male or female), socioeconomic status, acute-phase disease severity (mild, hospitalized, or severe), and vaccination status (unvaccinated, fully vaccinated, or fully vaccinated and boosted).
As part of sensitivity analyses, we subjected our analyses to a set of negative-outcome controls where no prior knowledge supports the existence of causal associations between SARS-CoV-2 exposure and the risks of negative-outcome controls. Specifically, we examined the risk of atopic dermatitis and various neoplasms (B-cell lymphoma, Hodgkin lymphoma, malignancy of tongue) post-SARS-CoV-2 infection as negative-outcome controls, in line with previously published approaches [5, 24], modified to remove conditions (eg. sickle-cell trait, melanoma) uncommon in our predominantly Asian population.
Estimation of variance when weightings were applied was accomplished using robust sandwich variance estimators, which were previously demonstrated to reproduce valid model estimates even under model misspecification [27]. A 95% confidence interval (CI) that excluded unity was considered evidence of statistical significance. Analyses were conducted using Stata version 16 software, and results were visualized using R version 4.04 software.
Ethics Statement
This study was done as part of national public health research under the Infectious Diseases Act, Singapore; ethics review by an institutional review board was not required.
RESULTS
Baseline Characteristics
We included 1 684 085 test-negative controls and 106 012 cases with documented SARS-CoV-2 infection in our study. Demographic and clinical characteristics of both SARS-CoV-2–infected and test-negative control groups before and after propensity score matching is presented in Table 1. The mean age of participants in the SARS-CoV-2–infected group was 51 years with 80.7% and 10.8% fully vaccinated and boosted, respectively. Around 55.8% were male and 68.2% of Chinese ethnicity (Table 1). After weighting, differences in baseline characteristics between the 2 groups were small (Table 1).
Table 1.
Baseline and Inverse Probability–Weighted Characteristics of the Study Population
| Characteristic | Cases (n = 106 012)a |
Controls (n = 1 684 085)a |
Cases, Weighted |
Controls, Weighted |
Weighted SMDb |
|---|---|---|---|---|---|
| Age, y, mean (SD) | 51 (17.25) | 48 (17.7) | 48 (17.0) | 48 (17.7) | 0.003 |
| Vaccination | |||||
| Unvaccinated | 9107 (8.59) | 113 145 (6.7) | 122 396 (6.8) | 122 246 (6.83) | 0.000 |
| Fully vaccinated | 85 500 (80.6) | 1 268 223 (75.3) | 1 345 416 (75.1) | 1 353 727 (75.6) | 0.012 |
| Boosted | 11 405 (10.8) | 302 717 (18.0) | 323 097 (18.0) | 314 139 (17.6) | 0.013 |
| Ethnicity | |||||
| Chinese | 72 252 (68.2) | 1 274 509 (75.7) | 134 7247 (75.2) | 1 346 724 (75.2) | 0.000 |
| Malay | 18 971 (17.9) | 197 121 (11.7) | 223 058 (12.5) | 216 162 (12.1) | 0.012 |
| Indian | 11 965 (11.3) | 156 435 (9.29) | 163 884 (9.2) | 168 385 (9.41) | 0.009 |
| Other | 2824 (2.7) | 56 020 (3.33) | 56 719 (3.2) | 58 841 (3.29) | 0.007 |
| Sex | |||||
| Male | 59 161 (55.8) | 810 035 (48.1) | 872 765 (48.7) | 869 203 (48.6) | 0.004 |
| Housing type | |||||
| 1–2 rooms | 8513 (8.03) | 71 102 (4.2) | 79 711 (4.5) | 79 622 (4.45) | 0.000 |
| 3 rooms | 24 684 (23.3) | 269 371 (16.0) | 294 540 (16.5) | 294 069 (16.4) | 0.001 |
| 4 rooms | 37 492 (35.4) | 533 771 (31.7) | 572 116 (32.0) | 571 263 (31.9) | 0.001 |
| 5 rooms/Executive condominium | 25 076 (23.7) | 424 788 (25.2) | 448 732 (25.1) | 449 859 (25.1) | 0.002 |
| Private housing | 10 247 (9.7) | 385 053 (22.9) | 395 809 (22.1) | 395 299 (22.1) | 0.000 |
| Comorbidities | |||||
| Cerebrovascular disorders | 341 (0.32) | 3997 (0.24) | 4383 (0.24) | 4351 (0.24) | 0.000 |
| Dysrhythmias | 413 (0.39) | 3871 (0.23) | 5433 (0.30) | 4193 (0.23) | 0.013 |
| Ischemic heart disease | 540 (0.51) | 5604 (0.33) | 6424 (0.36) | 6107 (0.34) | 0.003 |
| Other cardiac disorders | 320 (0.30) | 2585 (0.15) | 3310 (0.18) | 2850 (0.16) | 0.006 |
| Thrombotic disorders | 98 (0.09) | 920 (0.05) | 1201 (0.07) | 1003 (0.06) | 0.004 |
| Inflammatory heart disease | 3 (0.00) | 24 (0.00) | 41 (>0.00) | 25 (>0.00) | 0.002 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: COVID-19, coronavirus disease 2019; SD, standard deviation; SMD, standardized mean difference.
aNumber of cases and controls after inclusion and exclusion criteria were met.
bSMD after inverse probability weighting of cases (COVID-19–infected individuals) and controls (uninfected individuals).
We estimated the HRs of prespecified cardiovascular, cerebrovascular, and other thrombotic complications in the SARS-CoV-2–infected and test-negative control groups (Table 2).
Table 2.
Hazard Ratios and Excess Burdens of Prespecified Complications in the Coronavirus Disease 2019–Exposed Group and Control Groups
| Outcome | HR (95% CI)a | Excess Burden (95% CI) (Weighted, per 1000 Persons) | No. of Individuals | |||
|---|---|---|---|---|---|---|
| Controls | Controls With Outcome | Cases | Cases With Outcome | |||
| Composite outcomes | ||||||
| Any cardiovascular, cerebrovascular, and other thrombotic complication | 1.16 (1.07–1.25)b | 0.70 (.53–.88)b | 1 607 157 | 9970 | 99 214 | 912 |
| Major adverse cardiovascular/cerebrovascular events | 1.14 (1.02–1.26)b | 0.28 (.15–.40)b | 1 656 164 | 5657 | 103 215 | 560 |
| Cerebrovascular complications (eg, stroke, TIA) | 1.12 (.973–1.29) | 0.15 (.05–.24)b | 1 655 044 | 3276 | 103 439 | 290 |
| Cardiovascular complications | ||||||
| Dysrhythmias | 1.32 (1.15–1.52)b | 0.51 (.42–.61)b | 1 664 562 | 3071 | 104 408 | 311 |
| Ischemic heart diseases | 1.04 (.92–1.17) | 0.02 (−.08 to .13) | 1 652 224 | 4391 | 103 083 | 392 |
| Other cardiac disorders | 1.33 (1.14–1.55)b | 0.30 (.22–.37)b | 1 676 187 | 1895 | 105 132 | 236 |
| Inflammatory heart disease | 1.76 (.47–6.64) | 0.01 (.00–.02) | 1 683 885 | 23 | 105 994 | 3 |
| Other thrombotic complications (eg. pulmonary embolism, venous thromboses, arterial thromboses) | 1.22 (.94–1.58) | 0.08 (.04–.13)b | 1 680 478 | 809 | 105 662 | 84 |
| Individual outcomes | ||||||
| Stroke | 1.06 (.91–1.23) | 0.02 (−.07 to .10) | 1 658 327 | 2776 | 103 688 | 243 |
| TIA | 1.21 (.90–1.64) | 0.08 (.04–.13)b | 1 678 949 | 733 | 105 584 | 63 |
| Atrial fibrillation | 1.15 (.94–1.40) | 0.06 (−.00 to .13) | 1 675 638 | 1521 | 105 259 | 142 |
| Sinus tachycardia | 1.03 (.76–1.40) | 0.01 (−.03 to .05) | 1 680 493 | 652 | 105 716 | 58 |
| Sinus bradycardia | 1.64 (1.12–2.41)b | 0.10 (.07–.13)b | 1 682 277 | 272 | 105 859 | 39 |
| Other arrhythmia | 1.68 (1.34–2.12)b | 0.39 (.33–.45)b | 1 676 468 | 1006 | 105 420 | 118 |
| Myocardial infarction | 1.08 (.92–1.27) | 0.06 (−.03 to .14) | 1 671 974 | 2454 | 104 773 | 235 |
| Acute coronary disease | 0.96 (.83–1.11) | −0.11 (−.19 to −.02) | 1 661 961 | 2882 | 104 036 | 238 |
| Ischemic cardiomyopathy | 1.11 (.67–1.85) | 0.01 (−.01 to .04) | 1 682 982 | 228 | 105 866 | 21 |
| Angina | 1.24 (.96–1.61) | 0.11 (.06–.15)b | 1 673 700 | 802 | 105 038 | 87 |
| Heart failure | 1.28 (1.08–1.52)b | 0.18 (.11–.25)b | 1 677 494 | 1524 | 105 270 | 188 |
| Nonischemic cardiomyopathy | 1.63 (1.14–2.32)b | 0.11 (.08–.14)b | 1 682 194 | 297 | 105 813 | 43 |
| Cardiac arrest | 1.17 (.68–2.02) | 0.01 (−.01 to .03) | 1 683 998 | 188 | 106 000 | 19 |
| Cardiogenic shock | 0.76 (.36–1.60) | −0.01 (−.03 to −.00) | 1 683 937 | 81 | 106 000 | 8 |
| Pulmonary embolism | 1.13 (.68–1.85) | 0.01 (−.02 to .04) | 1 683 139 | 257 | 105 932 | 21 |
| Deep venous thrombosis | 1.12 (.82–1.54) | 0.03 (−.01 to .06) | 1 681 727 | 509 | 105 767 | 56 |
| Superficial venous thromboses | 1.78 (.83–3.84) | 0.04 (.02–.06)b | 1 683 640 | 88 | 105 970 | 10 |
| Arterial thromboses | 0.82 (.23–2.90) | −0.01 (−.02 to .00) | 1 683 809 | 47 | 105 990 | 3 |
| Pericarditis | …c | 0.02 (.01–.02)b | 1 683 951 | 13 | 105 998 | 3 |
| Myocarditis | …c | −0.01 (−.01 to −.00) | 1 684 013 | 12 | 106 008 | 0 |
HR >1 denotes higher risk of a respective composite/individual new cardiovascular, cerebrovascular, and other thrombotic complications in the coronavirus disease 2019 (COVID-19)–exposed group versus control group. Excess burden >0 denotes excess burden in a respective composite/individual new cardiovascular, cerebrovascular, and other thrombotic complications in the COVID-19–exposed group versus control group.
Abbreviations: CI, confidence interval; HR, hazard ratio; TIA, transient ischemic attack.
aEach model is inverse probability weighted and regression adjusted based on demographic characteristics (age, sex, ethnicity), socioeconomic status (housing type), vaccination status (not vaccinated, vaccinated, vaccinated and boosted), and comorbidity burden at baseline (constituent conditions in Charlson comorbidity index).
bDenotes 95% CIs that are bounded away from 0.
cNot estimable due to 0 myocarditis cases in the COVID-19–exposed group.
Among COVID-19 survivors, there were increased risks of both composite endpoints, namely MACE (HR, 1.14 [95% CI, 1.02–1.26]) and any cardiovascular, cerebrovascular, or other thrombotic complication (HR, 1.16 [95% CI, 1.07–1.25]) compared with the control group.
COVID-19 survivors did not exhibit higher risks of all cerebrovascular complications (HR, 1.12 [95% CI, .97–1.29]), such as stroke (HR, 1.056 [95% CI, .908–1.23]) and TIA (HR, 1.21 [95% CI, .90–1.64]), although there was a moderate weighted excess burden (EB) per 1000 persons in the COVID-19–exposed group for TIA (EB, 0.08 [95% CI, .04–.13]).
With respect to cardiovascular complications, there were increased risks and excess burdens of dysrhythmias (HR, 1.32 [95% CI, 1.15–1.52]), specifically, sinus bradycardia (HR, 1.64 [95% CI, 1.12–2.41]) and other arrhythmias (HR, 1.68 [95% CI, 1.34–2.12]), among the COVID-19 survivors. COVID-19 survivors did not exhibit higher risk of all inflammatory heart disease (HR, 1.76 [95% CI, .47–6.64]).
SARS-CoV-2 infection was not positively associated with all IHD (HR, 1.04 [95% CI, .92–1.17]). There was no increased risk of acute coronary disease (HR, 0.960 [95% CI, .83–1.11]), myocardial infarction (HR, 1.08 [95% CI, .92–1.27]) ischemic cardiomyopathy (HR, 1.11 [95% CI, .67–1.85]), or angina (HR, 1.24 [95% CI, .96–1.61]) in COVID-19 survivors. However, there was a moderate weighted excess burden per 1000 persons in the COVID-19 group for angina (EB, 0.11 [95% CI, .06–.15]).
There were increased risks of other cardiac disorders (HR, 1.33 [95% CI, 1.14–1.55]), namely, heart failure (HR, 1.28 [95% CI, 1.08–1.52]) and nonischemic cardiomyopathy (HR, 1.63 [95% CI, 1.14–2.32]).
Risk of other thrombotic complications (HR, 1.22 [95% CI, .94–1.58]), including pulmonary embolism (HR, 1.13 [95% CI, .68–1.85]), deep venous thrombosis (HR, 1.12 [95% CI, .815–1.54]), superficial vein thrombosis (HR, 1.78 [95% CI, .83–3.84]), and arterial thromboses (HR, 0.816 [95% CI, .230–2.90]), were not increased in COVID-19 survivors.
Subgroup Analysis
We examined the risk and excess burdens of new-incident complications in subgroups (Figure 2) based on vaccination status (unvaccinated, vaccinated, vaccinated and boosted), severity of acute infection (mild, hospitalized, severe), sex (male, female), age (18–65, ≥66 years), and socioeconomic status (by housing type). Full model estimates are provided in the Supplemental Tables 2–20.
Figure 2.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for composite cardiovascular, cerebrovascular, and other thrombotic complications according to severity, vaccination, main cohort, sex, and age group (in years). Points and lines represent point estimates for HRs and 95% CIs, respectively. Blank points represent inestimable HRs due to null counts in that specific subgroup for cases, controls, or both. Abbreviations: CI, confidence interval; COVID, coronavirus disease 2019; HR, hazard ratio.
Among nonhospitalized COVID-19 survivors, there was no increased risk of cardiovascular, cerebrovascular, and other thrombotic complications (Figure 2) except for dysrhythmias (HR, 1.20 [95% CI, 1.02–1.42]). However, risks of complications were increased in the hospitalized group, including cerebrovascular complications (HR, 3.23 [95% CI, 1.47–7.11]), dysrhythmias (HR, 2.67 [95% CI, 1.64–4.36]), IHD (HR, 1.487 [95% CI, 1.05–2.11]), other cardiac disorders (HR, 2.63 [95% CI, 1.79–3.87]), and other thrombotic complications (HR, 4.01 [95% CI, 2.03–7.91]).
Compared with the control group, we found that unvaccinated COVID-19 survivors had higher risk of various cardiovascular complications, including IHD (HR, 1.45 [95% CI, 1.07–1.95]), dysrhythmias (HR, 2.04 [95% CI, 1.53–2.72]), and other cardiac disorders (HR, 1.92 [95% CI, 1.39–2.65]). These effect sizes were also larger compared with the main analysis (Figure 2, Table 3). There was also increased risk for composite outcomes, including any cardiovascular, cerebrovascular, or other thrombotic complication (HR, 1.56 [95% CI, 1.29–1.90]) and MACE (HR, 1.51 [95% CI, 1.19–1.92]). However, vaccination and subsequent boosting decreased risk of new-incident complications associated in a graded fashion. Specifically, all HRs for the vaccinated COVID-19 survivors were smaller compared with estimates in the main analysis (Figure 2, Table 3). Overall, there were no increased risks of any cardiovascular, cerebrovascular, or other thrombotic complication (HR, 1.10 [95% CI, .92–1.32]) among boosted COVID-19 survivors. No HRs for individual complications were significant in the boosted group, except for other arrhythmia (HR, 2.20 [95% CI, 1.40–3.46]).
Table 3.
Hazard Ratios and Excess Burdens of Prespecified Cardiovascular, Cerebrovascular, or Other Thrombotic Complications in the Coronavirus Disease 2019 and Control Groups for Each Vaccination Subgroup
| Outcome | Unvaccinated | Fully Vaccinated | Boosted | |||
|---|---|---|---|---|---|---|
| HR (95% CI)a | Excess Burden (95% CI) (Weighted, per 1000 Persons) | HR (95% CI)a | Excess Burden (95% CI) (Weighted, per 1000 Persons) | HR (95% CI)a | Excess Burden (95% CI) (Weighted, per 1000 Persons) | |
| Composite outcomes | ||||||
| Any cardiovascular, cerebrovascular, and other thrombotic complication | 1.56 (1.29–1.90)b | 3.95 (3.14–4.75) | 1.11 (1.02–1.22)b | 0.41 (.24–.59) | 1.10 (.92–1.32) | 1.11 (.55–1.68) |
| Major adverse cardiovascular/cerebrovascular events | 1.51 (1.19–1.92)b | 2.13 (1.51–2.75) | 1.12 (.99–1.26) | 0.20 (.07–.33) | 1.05 (.81–1.35) | 0.27 (−.13 to .68) |
| Cerebrovascular complications (eg. stroke, TIA) | 1.25 (.89–1.76) | 0.61 (.16–1.05) | 1.04 (.88–1.22) | 0.01 (−.09 to .10) | 1.20 (.89–1.62) | 0.75 (.43–1.07) |
| Cardiovascular complications | ||||||
| Dysrhythmias | 2.04 (1.53–2.72)b | 2.58 (2.07–3.08) | 1.18 (1.00–1.40)b | 0.24 (.14–.33) | 1.38 (1.00–1.91)b | 1.12 (.82–1.42) |
| Ischemic heart diseases | 1.45 (1.07–1.95)b | 1.22 (.72–1.71) | 1.00 (.87–1.16) | −0.03 (−.14 to .08) | 0.98 (.75–1.29) | −0.10 (−.46 to .26) |
| Other cardiac disorders | 1.92 (1.39–2.65)b | 1.60 (1.19–2.02) | 1.43 (1.19–1.70)b | 0.31 (.24–.39) | 0.93 (.59–1.46) | −0.16 (−.38 to .06) |
| Inflammatory heart disease | …c | 0.00 (.00–.00) | 2.18 (.57–8.36) | 0.02 (.00–.03) | …c | −0.01 (−.03 to −.00) |
| Other thrombotic complications (eg. pulmonary embolism, venous thromboses, arterial thromboses) | 1.68 (.95–2.95) | 0.50 (.24–.76) | 1.30 (.95–1.79) | 0.11 (.05–.16) | 0.94 (.42–2.12) | −0.10 (−.22 to .03) |
| Individual outcomes | ||||||
| Stroke | 1.27 (.89–1.82) | 0.61 (.18–1.03) | 0.98 (.82–1.17) | −0.07 (−.16 to .01) | 1.13 (.80–1.59) | 0.39 (.10–.68) |
| TIA | 0.74 (.23–2.38) | −0.14 (−.30 to .02) | 1.20 (.83–1.73) | 0.06 (.02–.11) | 1.25 (.72–2.19) | 0.21 (.06–.37) |
| Atrial fibrillation | 1.65 (1.11–2.46)b | 0.84 (.50–1.18) | 1.14 (.90–1.44) | 0.05 (−.01 to .11) | 1.07 (.64–1.78) | 0.10 (−.11 to .31) |
| Sinus tachycardia | 2.59 (1.39–4.81)b | 0.92 (.66–1.18) | 0.82 (.56–1.19) | −0.07 (−.11 to −.03) | 0.95 (.40–2.26) | −0.03 (−.14 to .08) |
| Sinus bradycardia | 4.58 (1.49–14.07)b | 0.42 (.27–.58) | 1.40 (.87–2.25) | 0.05 (.02–.08) | 1.39 (.55–3.50) | 0.10 (.01–.18) |
| Other arrhythmia | 2.15 (1.29–3.60)b | 0.89 (.61–1.17) | 1.40 (1.05–1.86)b | 0.20 (.14–.26) | 2.20 (1.40–3.46)b | 1.13 (.94–1.32) |
| Myocardial infarction | 1.42 (.99–2.03) | 0.68 (.29–1.06) | 0.66 (.35–1.24) | −0.11 (−.19 to −.03) | 1.25 (.88–1.77) | 0.64 (.37–.91) |
| Acute coronary disease | 1.11 (.69–1.77) | 0.19 (−.14 to .52) | 0.97 (.82–1.15) | −0.05 (−.14 to .03) | 0.86 (.63–1.19) | −0.46 (−.75 to −.18) |
| Ischemic cardiomyopathy | 1.34 (.52–3.46) | 0.09 (−.06 to .24) | 0.81 (.39–1.66) | −0.02 (−.04 to .01) | 1.65 (.63–4.32) | 0.13 (.04–.22) |
| Angina | 2.17 (1.09–4.32)b | 0.46 (.26–.66) | 1.32 (.97–1.79) | 0.12 (.07–.17) | 0.82 (.44–1.51) | −0.15 (−.29 to −.01) |
| Heart failure | 2.04 (1.44–2.90)b | 1.48 (1.10–1.86) | 1.45 (1.19–1.77)b | 0.25 (.19–.32) | 0.70 (.39–1.26) | −0.51 (−.70 to −.32) |
| Nonischemic cardiomyopathy | 1.67 (.72–3.83) | 0.17 (.02–.32) | 1.48 (.98–2.23) | 0.07 (.04–.10) | 1.79 (.82–3.93) | 0.23 (.13–.33) |
| Cardiac arrest | 1.01 (.29–3.52) | 0.00 (−.14 to .14) | 0.75 (.10–5.95) | 0.00 (−.02 to .02) | 1.58 (.45–5.63) | 0.10 (.03–.18) |
| Cardiogenic shock | 0.61 (.22–1.68) | −0.02 (−.07 to .04) | 1.01 (.45–2.27) | −0.00 (−.02 to .01) | …c | −0.07 (−.10 to −.04) |
| Pericarditis | …c | 0.00 (.00–.00) | …c | 0.02 (.01–.03) | …c | −0.01 (−.02 to .00) |
| Myocarditis | …c | 0.00 (.00–.00) | …c | −0.01 (−.01 to −.00) | …c | −0.01 (−.02 to .00) |
| Pulmonary embolism | 1.52 (.46–5.06) | 0.13 (−.00 to .27) | 0.83 (.45–1.52) | −0.03 (−.05 to −.00) | 1.91 (.67–5.47) | 0.17 (.08–.26) |
| Deep venous thrombosis | 1.85 (.95–3.60) | 0.36 (.15–.56) | 1.27 (.87–1.86) | 0.06 (.02–.10) | 0.47 (.14–1.60) | −0.25 (−.34 to −.16) |
| Superficial venous thromboses | 1.47 (.21–10.35) | 0.03 (−.04 to .10) | 2.57 (1.13–5.87)b | 0.07 (.05–.09) | …c | −0.08 (−.11 to −.05) |
| Arterial thromboses | 1.30 (.45–3.75) | 0.05 (−.03 to .13) | 0.20 (.03–1.53) | −0.02 (−.03 to −.01) | 0.93 (.51–1.69) | 0.03 (−.01 to .07) |
HR >1 denotes higher risk of a respective composite/individual new cardiovascular, cerebrovascular, or other thrombotic complication in the coronavirus disease 2019 (COVID-19)–exposed group versus control group. Excess burden >0 denotes excess burden in a respective composite/individual new cardiovascular, cerebrovascular, or other thrombotic complication in the COVID-19–exposed group versus control group.
Abbreviations: CI, confidence interval; HR, hazard ratio; TIA, transient ischemic attack.
aEach model is inverse probability weighted and regression adjusted based on demographic characteristics (age, sex, ethnicity), socioeconomic status (housing type), vaccination status (not vaccinated, vaccinated, vaccinated and boosted), and comorbidity burden at baseline (constituent conditions in Charlson comorbidity index).
bDenotes 95% CIs that are bounded away from 0.
cNot estimable due to 0 cases in either group.
Subgroup analysis based on sex and age did not change HR estimates drastically (Figure 2; Supplementary Tables 2–5).
Sensitivity Analyses
For conditions included as negative-outcome controls, such as B-cell lymphoma, malignancy of tongue, and atopic dermatitis, all HRs had CIs that were found to cross the zero bound (Supplementary Table 20).
DISCUSSION
In our large retrospective population-wide cohort study involving 2 912 069 test-negative controls and 111 799 cases infected during transmission of the Delta variant, infected individuals had higher risks of specific cardiovascular complications, including dysrhythmias and other cardiac disorders—such as heart failure and nonischemic cardiomyopathy—in the 300-day follow-up period postinfection. Chronic inflammation arising from residual viral reservoirs persisting in cardiac tissue or an autoimmune response to cardiac antigens may result in tissue damage and myocardial fibrosis, leading to impaired ventricular contractility and potential reentrant arrhythmias [2, 3]. Virus-induced lung injury may also induce right ventricular dysfunction through increasing pulmonary vascular resistance and right ventricular strain [28]. Prospective observational studies have documented persistent rate and rhythm abnormalities even after relatively mild infection [29, 30] and, similarly, reductions in left ventricular ejection fraction, right ventricular function, and diastolic dysfunction 3–9 months after acute COVID-19 [30, 31]. Further studies are needed to clarify the potential pathophysiological mechanism underlying these associations.
In our multiethnic Southeast Asian population, we reported 1.45–2.04 times higher risk of various cardiovascular complications, including IHD, dysrhythmias, and other cardiac disorders in the unvaccinated, infected group. These results are consistent with Xie et al, who reported approximately 1.5–2.0 times higher risk of various cardiovascular complications postinfection among US Veterans [5]. However, we did not observe elevated thrombotic risk, in contrast to other studies demonstrating increased risk of thrombotic complications in the United States (US) and United Kingdom [5–11]. Asian populations may have different thrombogenic phenotypes [32]. In the acute phase of COVID-19, <2% of a multicenter Japanese cohort had thrombotic complications [33], compared with rates of 7%–14% reported from a pooled meta-analysis of hospitalized studies conducted in Western populations [34]. Additional studies evaluating post-COVID-19 complications in other Asian populations are warranted.
In our study, the risk of cardiovascular complications postacute infection was evident even in mild cases who were not hospitalized. Large population-based studies in the US have demonstrated a similar dose-response relationship with increasing severity [5, 8, 34]. Risk was increasingly attenuated if individuals were vaccinated/boosted; similarly, Al-Aly et al reported lower risk of new-incident cardiovascular and cerebrovascular complications in vaccinated US Veterans with breakthrough SARS-CoV-2 infection compared with unvaccinated cases [11]. We did not observe significantly increased risk of individual cardiovascular, cerebrovascular, or other thrombotic complications in the boosted group, except for other arrhythmias. Electrocardiographic and cardiac conduction abnormalities are not uncommonly reported among unvaccinated patients on long-term follow-up with moderate to severe COVID-19; in a Chinese cohort, 16.3% reported arrhythmias at 12 months postdischarge [35]. While periodic boosters are required as part of prevention strategies to ameliorate postacute sequelae, this alone may not fully mitigate risks, given waning [36] and possible vaccine escape with new variants [37]. While the excess burdens of post-COVID-19 cardiovascular and cerebrovascular complications seem small (<10 per 1000 person-), the long-term burden of cardiovascular complications may be substantial. Updates to vaccination, such as bivalent vaccines, and early treatment with therapeutics [38] will potentially play a key role in mitigating the risks of long-term sequelae of post-SARS-CoV-2 infection.
Our study has the following limitations. The control group might be contaminated by undiagnosed or asymptomatic SARS-CoV-2 infections, causing differential misclassification bias. Misclassification would bias estimated HRs and excess burdens downward, resulting in more conservative estimates. However, we utilized a comprehensive nationwide testing database during a period when diagnostic tests were widely available in primary care, testing was free and strongly encouraged, and reporting was mandatory [18]. Our cohort comprised a predominantly Chinese (75.23%) population, which may limit generalizability. While we used a large, comprehensive national healthcare claims database to examine a prespecified, comprehensive list of complications, we cannot rule out unobserved confounding. We did not adjust for several important comorbidities (hypertension and obesity) as physiological measurements (eg, blood pressure, body mass index) were not recorded in electronic health records. Survivor bias may also result in underestimates of the HR reported for various outcomes.
CONCLUSIONS
In a national cohort of Delta-infected individuals, increased risk and burden of new-incident cardiovascular/cerebrovascular complications was demonstrated 300 days postinfection. Risks increased in a graded fashion according to initial severity; vaccination and boosting significantly attenuated risk.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Supplementary Material
Contributor Information
Jue Tao Lim, Lee Kong Chian School of Medicine, Nanyang Technological University; National Centre for Infectious Diseases.
Wee Liang En, National Centre for Infectious Diseases; Duke-NUS Graduate Medical School, National University of Singapore; Department of Infectious Diseases, Singapore General Hospital.
An Ting Tay, Singapore Ministry of Health.
Deanette Pang, Singapore Ministry of Health.
Calvin J Chiew, National Centre for Infectious Diseases; Singapore Ministry of Health.
Benjamin Ong, Singapore Ministry of Health; Yong Loo Lin School of Medicine, National University of Singapore.
David Chien Boon Lye, Lee Kong Chian School of Medicine, Nanyang Technological University; National Centre for Infectious Diseases; Yong Loo Lin School of Medicine, National University of Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital.
Kelvin Bryan Tan, Lee Kong Chian School of Medicine, Nanyang Technological University; Singapore Ministry of Health; Saw Swee Hock School of Public Health, National University of Singapore.
Notes
Financial support. J. T. L. is supported by the Ministry of Education, Singapore (Start-up Grant).
References
- 1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27:601–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J 2022; 43:1157–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis. Neurology 2021; 97:e2269–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372:n693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28:583–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Rezel-Potts E, Douiri A, Sun X, Chowienczyk PJ, Shah AM, Gulliford MC. Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK. PLoS Med 2022; 19:e1004052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Knight R, Walker V, Ip S, et al. Association of COVID-19 with Major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation 2022; 146:892–906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine 2022; 53:101619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. DeVries A, Shambhu S, Sloop S, Overhage JM. One-year adverse outcomes among US adults with post-COVID-19 condition vs those without COVID-19 in a large commercial insurance database. JAMA Health Forum 2023; 4:e230010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Wan EYF, Mathur S, Zhang R, et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK biobank. Cardiovasc Res 2023; 119:1718–27. [DOI] [PubMed] [Google Scholar]
- 11. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28:1461–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Gottlieb M, Wang R, Yu H, et al. Severe fatigue and persistent symptoms at three months following SARS-CoV-2 infections during the pre-Delta, Delta, and Omicron time periods: a multicenter prospective cohort study. Clin Infect Dis 2023;76:1930–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Ballouz T, Menges D, Kaufmann M, et al. Post COVID-19 condition after wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts. PLoS One 2023; 18:e0281429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA 2022; 328:887–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Jiang J, Chan L, Kauffman J, et al. Impact of vaccination on major adverse cardiovascular events in patients with COVID-19 infection. J Am Coll Cardiol 2023; 81:928–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Cutler DM, Summers LH. The COVID-19 pandemic and the $16 trillion virus. JAMA 2020; 324:1495–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Tan CC, Lam CSP, Matchar DB, Zee YK, Wong JEL. Singapore’s health-care system: key features, challenges, and shifts. Lancet 2021; 398:1091–104. [DOI] [PubMed] [Google Scholar]
- 18. Ministry of Health, Singapore . Streamlining of COVID-19 Healthcare Protocols. 2022. Available at: https://www.cfps.org.sg/assets/1-Circular-for-GPs/Covid-19-Mgmt-Protocols/3-MOH-Cir-No-07-2022-22Jan22-Streamlining-Covid-19-Healthcare-Protocols-final.pdf. Accessed 16 August 2023.
- 19. Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open 2022; 5:e2228900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Ministry of Health, Singapore . Update on local COVID-19 situation.2021. Available at: https://www.moh.gov.sg/news-highlights/details/update-on-local-covid-19-situation-(26-nov-2021). Accessed 23 January 2023.
- 21. Ministry of Health, Singapore . Adjusting our approach to manage the Omicron variant.2021. Available at:https://www.moh.gov.sg/news-highlights/details/adjusting-our-approach-to-manage-the-omicron-variant_26Dec2021. Accessed 16 March 2023.
- 22. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594:259–64. [DOI] [PubMed] [Google Scholar]
- 23. Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun 2021; 12:6571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022; 28:2398–405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Lim DYZ, Wong TH, Feng M, Ong MEH, Ho AFW. Leveraging open data to reconstruct the Singapore housing index and other building-level markers of socioeconomic status for health services research. Int J Equity Health 2021; 20:218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Thompson EJ, Williams DM, Walker AJ, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun 2022; 13:3528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84:1074–8. [Google Scholar]
- 28. Li Y, Li H, Zhu S, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc Imaging 2020; 13:2287–99. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Zhou M, Wong CK, Un KC, et al. Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS One 2021; 16:e0246732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Ingul CB, Grimsmo J, Mecinaj A, et al. Cardiac dysfunction and arrhythmias 3 months after hospitalization for COVID-19. J Am Heart Assoc 2022; 11:e023473. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur Heart J 2022; 43:1124–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Ki YJ, Jeong YH. Thrombosis and anticoagulation in East Asian patients with COVID-19: another phenotype of “East Asian paradox.” JACC Asia 2022; 2:908–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Nishimoto Y, Yachi S, Takeyama M, et al. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: from the CLOT-COVID study. J Cardiol 2022; 80:285–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 2021; 76:970–9. [DOI] [PubMed] [Google Scholar]
- 35. Liu T, Wu D, Yan W, et al. Twelve-month systemic consequences of coronavirus disease 2019 (COVID-19) in patients discharged from hospital: a prospective cohort study in Wuhan, China. Clin Infect Dis 2022; 74:1953–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Wee LE, Pang D, Chiew C, et al. Long-term real-world protection afforded by third mRNA doses against symptomatic severe acute respiratory syndrome coronavirus 2 infections, coronavirus disease 19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave. Clin Infect Dis 2023; 77:1111–9. [DOI] [PubMed] [Google Scholar]
- 37. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med 2023; 29:344–7. [DOI] [PubMed] [Google Scholar]
- 38. Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med 2023; 183:554–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.